ZTS three-lens brief
Evidence-based stock research on ZTS. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $150.29 — 29% above current (17 analysts). · Trading at 6% of its 52-week range — deep in the lower band.
- Trading at 6% of its 52-week range — deep in the lower band.
- Analyst mean target $150.29 — 29% above current (17 analysts).
- Debt-to-equity of 279.6 — balance-sheet-heavy.
ZTS closed at $116.87 (+0.70%) as of 2026-04-25. Market cap: $49.33B. P/E (trailing) 19.4. Positives: analyst mean target $150.29 — 29% above current (17 analysts).. Concerns: trading at 6% of its 52-week range — deep in the lower band.; debt-to-equity of 279.6 — balance-sheet-heavy.. Last quarter: Revenue $2.39B, net income $603.00M, free cash flow $1.79B.
Why three lenses on ZTS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ZTSacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ZTS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ZTS brief"></iframe>